We claim:

1. A pharmaceutical product or medicament comprising a first component selected from

- 5,6-dihydroxy-2-{3-[4-(2-isopropoxyphenyl)-piperazin-1-yl]propyl}-hexahydro-isoindole-1,3-dione,
- 1-{3-[4-(2-isopropoxyphenyl)piperazin-1-yl]propyl}-piperidine-2,6-dione,
- 2-{3-[4-(2-ethoxyphenyl)piperazin-1-yl]propyl}-3a,4,7,7a-tetrahydro-isoindole-1,3-dione,
- 1-(3-{4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl}propyl)piperidine-2,6-dione,
- 5-hydroxy-2-(3-{4-[2-(2,2,2-trifluoroethoxy)phenyl]-piperazin-1-yl}propyl)-hexahydro-isoindole-1,3-dione,
- 2-{3-[4-(2-Ethoxyphenyl)piperazin-1-yl]propyl}-5-hydroxy-hexahydro-isoindole-1,3-dione,
- 2-{3-[4-(2-Ethoxyphenyl)piperazin-1-yl]propyl}-5,6-dihydroxy-isoindole-1,3-dione,
- 4,7-dihydroxy-2-{3-[4-(2-isopropoxyphenyl)-piperazin-1-yl]propyl}-hexahydro-isoindole-1,3-dione,
- 3-Allyl-1-{3-[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-4-methyl-pyrrolidine-2,5-dione,
- 1-(2-Hydroxy-3-{4-[2-(2,2,3,3,3-pentafluoropropoxy)phenyl]-piperazin-1-yl}propyl)-piperidine-2,6-dione

or their pharmaceutically acceptable salts,

a second component comprising a muscarinic receptor antagonist,

an optional third component comprising testosterone 5α-reductase inhibitor and a pharmaceutically acceptable carrier.

2. A product or medicament according to claim 1 wherein the product or medicament is a combined preparation.

3. A product or medicament according to claim 2 wherein the combined preparation is a single dosage form.

4. A product or medicament according to claim 2 wherein the combined preparation comprise different dosage forms.

5. A product or medicament according to claim 1 wherein the muscarinic receptor antagonist is selected from

- (R)-2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-methyl-phenol,
- (S)-alpha-cyclohexyl-alpha-hydroxybenzaeneacetic acid-4-(diethylamino)-2-butynyl ester,
- (S)-1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]alpha,alpha-diphenyl-3-pyrrolidine acetamide,
- (1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate,
- 2-[(1R)-3-(diisopropylamine)-1-phenylpropyl]-4-(hydroxymethyl)phenyl isobutyrate,
- 2-Methyl-α,α-diphenyl-iH-imidazole,
- (2R)(+)(1α, 5α, 6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide,
- (2R, 2S) (1α, 5α, 6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide,
- (2R) (1α, 5α, 6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide,
- (2S) (1α, 5α, 6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide

or their pharmaceutically acceptable salts.

6. A product or medicament according to claim 1 wherein the testosterone 5α-reductase inhibitor is a type 1 or a type 2 or both a type 1 and type 2 or a dual type 1 and type 2 inhibitor.

7. A product or medicament according to claim 6 wherein the testosterone 5α-reductase inhibitor is a dual type 1 and type 2 inhibitor.

8. A product or medicament according to claim 7 wherein the dual type 1 and type 2 inhibitor is dutasteride.

9. A product or medicament according to claim 6 wherein the testosterone 5α-reductase inhibitor is a type 2 inhibitor.

10. A product or medicament according to claim 9 wherein the type 2 inhibitor is finasteride.

11. A method for treatment of a mammal suffering from benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS) associated with or without BPH, comprising administering to said mammal, a therapeutically effective amount of a product or medicament, comprising

- 5,6-dihydroxy-2-{3-[4-(2-isopropoxyphenyl)-piperazin-1-yl]propyl}-hexahydro-isoindole-1,3-dione,
- 1-{3-[4-(2-isopropoxyphenyl)piperazin-1-yl]propyl}-piperidine-2,6-dione,
- 2-{3-[4-(2-ethoxyphenyl)piperazin-1-yl]propyl}-3a,4,7,7a-tetrahydro-isoindole-1,3-dione,
- 1-(3-{4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl}propyl)piperidine-2,6-dione,
- 5-hydroxy-2-(3-{4-[2-(2,2,2-trifluoroethoxy(phenyl]-piperazin-1-yl}propyl)-hexahydro-isoindole-1,3-dione,
- 2-{3-[4-(2-ethoxyphenyl)piperazin-1-yl]propyl}-5-hydroxy-hexahydro-isoindole-1,3-dione,
- 2-{3-[4-(2-ethoxyphenyl)piperazin-1-yl]propyl}-5,6-dihydroxy-isoindole-1,3-dione,
- 4,7-dihydroxy-2-{3-[4-(2-isopropoxyphenyl)-piperazin-1-yl]propyl}-hexahydro-isoindole-1,3-dione,
- 3-allyl-1-{3-[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-4-methyl-pyrrolidine-2,5-dione,
- 1-(2-Hydroxy-3-{4-[2-(2,2,3,3,3-pentafluoropropoxy)phenyl]-piperazin-1-yl}propyl)-piperidine-2,6-dione

or their pharmaceutically acceptable salts, a muscarinic receptor antagonist and optionally included testosterone 5α-reductase inhibitor.

12. The method according to claims 11 wherein mammal is animal.

13. The method according to claims 11 wherein mammal is human.

14. The method according to claim 13 wherein human is man.

15. The method according to claim 13 wherein human is woman.

16. The method according to claims 11 wherein the said product or medicament is administered as a combined preparation.

17. The method according to claim 16 wherein the combined preparation is administered as single dosage forms.

18. The method according to claim 16 wherein the combined preparation is administered in different dosage form.

19. The method according to claim 18 wherein the different dosage forms are administered simultaneously.

20. The method according to claim 18 wherein the different dosage forms are administered separately.

21. The method according to claim 18 wherein the different dosage forms are administered sequentially.

22. The method according to claims 11 wherein muscarinic receptor antagonist is selected from

- (R)-2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-methyl-phenol (tolerodine),
- (S)-alpha-cyclohexyl-alpha-hydroxybenzaeneacetic acid-4-(diethylamino)-2-butynyl ester (oxybutynin),
- (S)-1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]alpha,alpha-diphenyl-3-pyrrolidine acetamide (darifenacin),
- (1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (solifenacin),
- 2-[(1R)-3-(diisopropylamine)-1-phenylpropyl]-4-(hydroxymethyl)phenyl isobutyrate,
- 2-Methyl-α,α-diphenyl-iH-imidazole and its pharmaceutically acceptable salts,
- (2R)(+)(1α, 5α, 6α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide,
- (2R, 2S) (1α, 5α, 6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide,

- (2R) (1α, 5α, 6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide,

- (2S) (1α, 5α, 6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide

and their pharmaceutically acceptable salts.

23. The method according to claim 11 wherein said testosterone 5α-eductase inhibitor is a type 1 or a type 2 or both a type 1 and type 2 or a dual type 1 and type 2 inhibitor.

24. The method according to claim 23 wherein the testosterone 5α-reductase inhibitor is a dual type 1 and type 2 inhibitor.

25. The method according to claim 24 wherein the dual type 1 and type 2 inhibitor is dutasteride.

26. The method according to claim 23 wherein the testosterone 5α-reductase inhibitor is a type 2 inhibitor.

27. The method according to claim 26 wherein the type 2 inhibitor is finasteride.

28. A pharmaceutical product or medicament comprising a first pharmaceutical composition of a component selected from

- 5,6-dihydroxy-2-{3-[4-(2-isopropoxyphenyl)-piperazin-1-yl]propyl}-hexahydro-isoindole-1,3-dione,

- 1-{3-[4-(2-isopropoxyphenyl)piperazin-1-yl]propyl}-piperidine-2,6-dione,

- 2-{3-[4-(2-ethoxyphenyl)piperazin-1-yl]propyl}-3a,4,7,7a-tetrahydro-isoindole-1,3-dione,

- 1-(3-{4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl}propyl)piperidine-2,6-dione,

- 5-hydroxy-2-(3-{4-[2-(2,2,2-trifluoroethoxy)phenyl]-piperazin-1-yl}propyl)-hexahydro-isoindole-1,3-dione,

- 2-{3-[4-(2-Ethoxyphenyl)piperazin-1-yl]propyl}-5-hydroxy-hexahydro-isoindole-1,3-dione,

- 2-{3-[4-(2-Ethoxyphenyl)piperazin-1-yl]propyl}-5,6-dihydroxy-isoindole-1,3-dione,

- 4,7-dihydroxy-2-{3-[4-(2-isopropoxyphenyl)-piperazin-1-yl]propyl}-hexahydro-isoindole-1,3-dione,

- 3-Allyl-1-{3-[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-4-methyl-pyrrolidine-2,5-dione,

- 1-(2-Hydroxy-3-{4-[2-(2,2,3,3,3-pentafluoropropoxy)phenyl]-piperazin-1-yl}propyl)-piperidine-2,6-dione

or their pharmaceutically acceptable salts,

a second pharmaceutical composition of a muscarinic receptor antagonist,

an optional third pharmaceutical composition of testosterone 5α-reductase inhibitor.